10x Genomics Dl Stock Beta
| 1KJ Stock | EUR 12.61 0.07 0.56% |
10X GENOMICS DL fundamentals help investors to digest information that contributes to 10X GENOMICS's financial success or failures. It also enables traders to predict the movement of 10X Stock. The fundamental analysis module provides a way to measure 10X GENOMICS's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to 10X GENOMICS stock.
10X |
10X GENOMICS DL Company Beta Analysis
10X GENOMICS's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current 10X GENOMICS Beta | 1.67 |
Most of 10X GENOMICS's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, 10X GENOMICS DL is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, 10X GENOMICS DL has a Beta of 1.6741. This is 94.66% higher than that of the Healthcare sector and significantly higher than that of the Health Information Services industry. The beta for all Germany stocks is notably lower than that of the firm.
10X Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses 10X GENOMICS's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of 10X GENOMICS could also be used in its relative valuation, which is a method of valuing 10X GENOMICS by comparing valuation metrics of similar companies.10X GENOMICS is number one stock in beta category among its peers.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, 10X GENOMICS will likely underperform.
10X Fundamentals
| Return On Equity | -0.21 | |||
| Return On Asset | -0.0892 | |||
| Profit Margin | (0.33) % | |||
| Operating Margin | (0.28) % | |||
| Shares Outstanding | 95.6 M | |||
| Shares Owned By Insiders | 2.60 % | |||
| Shares Owned By Institutions | 99.56 % | |||
| Revenue | 503.71 M | |||
| Gross Profit | 416.4 M | |||
| EBITDA | (117.15 M) | |||
| Net Income | (504.02 M) | |||
| Cash And Equivalents | 621.96 M | |||
| Cash Per Share | 5.66 X | |||
| Total Debt | 70.82 M | |||
| Debt To Equity | 0.09 % | |||
| Current Ratio | 6.69 X | |||
| Book Value Per Share | 6.78 X | |||
| Cash Flow From Operations | (219.4 M) | |||
| Earnings Per Share | (0.76) X | |||
| Target Price | 197.56 | |||
| Number Of Employees | 1.24 K | |||
| Beta | 1.67 | |||
| Market Capitalization | 5.23 B | |||
| Z Score | 43.8 |
About 10X GENOMICS Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze 10X GENOMICS DL's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of 10X GENOMICS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of 10X GENOMICS DL based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in 10X Stock
10X GENOMICS financial ratios help investors to determine whether 10X Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in 10X with respect to the benefits of owning 10X GENOMICS security.